Analgesic use and risk of renal cell carcinoma in two US populations

Tuesday, September 23, 2014 — Poster Session III
12:00 p.m. – 2:00 p.m.	FAES Academic Center	NCI	EPIG-4

Authors

• S Karami
• SE Daughtery
• K Schwartz
• FG Davis
• JJ Ruterbusch
• S Wacholder
• BI Graubard
• MP Purdue
• LE Moore
• JS Colt

Abstract

Worldwide analgesics are the most commonly consumed drugs. Evidence that analgesics increase kidney cancer risk is mixed. We investigated the association between renal cell carcinoma (RCC) and analgesic use in the population-based case-control US Kidney Cancer Study (n=1,217 cases/1,235 controls) and the multi-center randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (n=98,807; 137 RCC cases). Information on use of acetaminophen, aspirin, and non-steroid anti-inflammatory drugs (NSAIDs) was self-reported. For the case-control study, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression. For PLCO, we computed hazard ratios (HRs) and 95%CIs using Cox regression. We conducted a meta-analysis to summarize epidemiological evidence for acetaminophen use and kidney cancer risk. In the US Kidney Cancer Study, RCC risk was associated with over-the-counter acetaminophen use (OR=1.35, 95%CI=1.01-1.83) with a positive trend with increasing duration of use (p-trend=0.01). In PLCO, acetaminophen users had elevated risk (HR=1.68, 95%CI=1.19-2.39) but with no trend for duration. Associations were null for aspirin and NSAIDs in both studies. Meta-analytic cohort (n=4, summary relative risk=1.34; 95%CI=1.13-1.59; Pheterogeneity=0.40) and case-control (n=9, summary OR=1.20; 95%CI=1.01-1.42; Pheterogeneity=0.05) findings support an association between acetaminophen use and kidney cancer. Acetaminophen use may increase the risk of developing RCC.

back to top